Skip to content
ClinCalc Pro
Menu
Mood stabiliser (liquid) Pregnancy: Should not be used during pregnancy, especially during the first trimester, unless considered essential - there is epidemiological evidence of harm to the foetus and lithium crosses the placenta, with an increase in cardiac and other abnormalities, especially Ebstein anomaly, reported. Pre-natal ultrasound and electrocardiogram examination are strongly recommended. It is strongly recommended that lithium be discontinued before a planned pregnancy; if continued, monitor serum levels closely as renal function changes through pregnancy and suddenly at parturition. Discontinue shortly before delivery and recommence a few days post-partum; observe the neonate for lithium toxicity (lethargy, flaccid tone, hypotonia). Contraindicated in breast-feeding - bottle feeding is recommended. Women of child-bearing potential should adopt adequate contraception. (SPC 4.6 / 4.3)

Lithium citrate

Brand names: Li-Liquid, Priadel liquid

Lithium citrate is a lithium salt used as a mood stabiliser in the treatment and prophylaxis of bipolar disorder and recurrent depression, and to control mania.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: In patients of average weight (70 kg), an initial total daily dose of 1018-3054 mg lithium citrate (equivalent to 400-1200 mg lithium carbonate, which is 5-15 mL of liquid), given in divided doses in the morning and in the evening
Route: Oral (lithium citrate oral liquid) - for oral administration only
Frequency: Twice daily, morning and evening; the liquid should be taken at the same time every day
Max: Titrated to serum level, not to a fixed mg maximum - serum lithium levels of more than 1.5 mmol/L must be avoided
Dosage must be individualised depending on serum lithium levels and clinical response; the minimum effective dose should be sought and maintained. Measure serum lithium four to a maximum of seven days after starting treatment; adjust the dose to maintain the serum level permanently within the diurnal range 0.5-1.0 mmol/L, with a 12-hour target of 0.5-0.8 mmol/L (take blood before a dose is due and not less than 12 hours after the previous dose). Monitor weekly until stabilisation, then intervals may be increased gradually but should not normally exceed two to three months; re-measure after dose changes, intercurrent disease, signs of manic or depressive relapse, significant changes in sodium or fluid intake, or signs of toxicity. Acute mania, hypomania and recurrent bipolar depression: a higher than normal intake may be necessary - maintain serum levels at 0.8-1.2 mmol/L until acute symptoms are controlled (not exceeding 1.5 mmol/L), then re-determine the level and re-stabilise to the prophylactic dose. Elderly patients or those below 50 kg: start 509 mg lithium citrate (equivalent to 200 mg lithium carbonate, which is 2.5 mL of liquid) in divided doses morning and evening; elderly patients may be more sensitive and long-term patients often require dose reduction over a period of years. Lithium therapy should not be initiated unless adequate facilities for routine monitoring of serum concentrations are available. Do not take a double dose to make up for a missed dose. If lithium is to be discontinued, particularly from high doses, reduce the dose gradually. When changing between lithium preparations, check the serum level first and start at a daily dose as close as possible to the previous form - bioavailability varies from product to product, so a change of product should be regarded as initiation of new treatment. Full prophylactic effect may not occur for 6 to 12 months. Children and adolescents: not recommended. eMC SPC section 4.2.

Dose adjustments

Renal

Mild and moderate renal insufficiency: serum lithium levels must be closely monitored and the dose adjusted accordingly to keep levels within the recommended range; if very regular and close monitoring of serum lithium and plasma creatinine is not possible, lithium should not be prescribed in this population. Contraindicated in severe renal insufficiency. (SPC 4.2 / 4.4 / 4.3)

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • History of hypersensitivity to lithium or to any of the excipients
  • Severe renal insufficiency
  • Cardiac disease and cardiovascular insufficiency
  • Untreated hypothyroidism
  • Low body sodium levels - including dehydrated patients, those on low sodium diets, and those with Addison's disease
  • Brugada syndrome or family history of Brugada syndrome
  • Breast-feeding

Side effects

  • Tremor, especially fine hand tremor; also ataxia, slurred speech, dizziness, giddiness and memory impairment - symptoms that may result in falls
  • Polydipsia and/or polyuria, nephrogenic diabetes insipidus; interstitial renal changes on long-term treatment
  • Thyroid disturbance - euthyroid goitre and/or hypothyroidism, thyrotoxicosis; hypercalcaemia (very frequent) and hyperparathyroidism
  • Gastrointestinal - nausea, vomiting, diarrhoea, abdominal discomfort, dry mouth, taste disorder, anorexia (mild GI effects often settle after the first few days)
  • Cardiac - bradycardia and sinus node dysfunction, hypotension, reversible T-wave flattening or inversion, QT prolongation, AV block, unmasking of Brugada syndrome
  • Weight increase, hyperglycaemia, thirst; leucocytosis; skin reactions including acneform eruptions and aggravation of psoriasis

Interactions

  • Diuretics - diuretic-induced sodium loss reduces lithium clearance and increases serum lithium; monitor electrolytes and lithium more frequently and reduce the dose (US label 7.1; eMC 4.4 warns about drugs likely to upset electrolyte balance)
  • NSAIDs - decrease renal blood flow and increase serum lithium concentrations; monitor more frequently and reduce the dose (US label 7.1)
  • Renin-angiotensin system antagonists and metronidazole - may increase lithium serum concentrations (US label 7)
  • Serotonergic agents - increased risk of serotonin syndrome (US label 7.1)
  • Antipsychotics - neurologic adverse reactions ranging from extrapyramidal symptoms to neuroleptic malignant syndrome (US label 7.1)
  • Salt/water depletion of any cause (vomiting, diarrhoea, excessive sweating, severe dieting) raises lithium concentrations - monitor closely and adjust (eMC 4.4)

Clinical monograph

How it works

Its precise mechanism is uncertain, but lithium is thought to modulate neuronal signal transduction, including effects on second-messenger systems, to stabilise mood.

Prescribing in practice

  • Lithium has a narrow therapeutic index, and toxicity can be life-threatening, so serum lithium concentrations must be monitored and patients warned about precipitants such as dehydration, infection and interacting drugs.
  • Different lithium preparations vary in bioavailability, so the brand should not be changed without re-checking serum levels.
  • Renal, thyroid and cardiac function require assessment before and during treatment, as lithium can affect the kidneys and thyroid.

Monitoring

Monitor serum lithium concentrations regularly, together with renal and thyroid function, and review for signs of toxicity such as tremor, vomiting, diarrhoea and confusion.

Counselling the patient

  • Maintain a consistent fluid and salt intake and avoid becoming dehydrated.
  • Carry a lithium alert card and attend for blood tests as scheduled.
  • Seek urgent advice for coarse tremor, persistent vomiting, diarrhoea or drowsiness.

Evidence & guidelines

Lithium is a long-established, evidence-based mood stabiliser recommended by NICE for bipolar disorder, with the MHRA emphasising the need for routine monitoring.

Reference: NICE CG185; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.